Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
Lancet Gastroenterol Hepatol. 2023 May;8(5):446-457. doi: 10.1016/S2468-1253(22)00428-9. Epub 2023 Mar 7.
Lancet Gastroenterol Hepatol. 2023.
PMID: 36898393
Clinical Trial.
Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease.
Daveson AJM, Tye-Din JA, Goel G, Goldstein KE, Hand HL, Neff KM, Williams LJ, Truitt KE, Anderson RP; RESET CeD Study Group.
Daveson AJM, et al.
Aliment Pharmacol Ther. 2020 Jan;51(2):244-252. doi: 10.1111/apt.15551. Epub 2019 Nov 26.
Aliment Pharmacol Ther. 2020.
PMID: 31769533
Clinical Trial.
Item in Clipboard
Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease.
Tye-Din JA, Daveson AJM, Goldstein KE, Hand HL, Neff KM, Goel G, Williams LJ, Truitt KE, Anderson RP; RESET CeD Study Group.
Tye-Din JA, et al.
BMC Med. 2020 Nov 26;18(1):362. doi: 10.1186/s12916-020-01828-y.
BMC Med. 2020.
PMID: 33239013
Free PMC article.
Item in Clipboard
Cite
Cite